To include your compound in the COVID-19 Resource Center, submit it here.

FDA imposes more stringent guidelines for opioids

FDA is imposing a more stringent set of requirements for immediate-release (IR) opioid formulations and issuing guidelines for development of generic versions of abuse-deterrent formulations in a bid to address the opioid epidemic in the

Read the full 358 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE